

EMPLOYEE HEALTH SERVICES

COUNTY WORKFORCE MEMBER HAZARDOUS DRUGS SPECIALTY MEDICAL EVALUATION

See GENERAL INSTRUCTIONS on Last Page

| LAST NAME: | FIRST, MIDDLE NAME: | | BIRTHDATE: | | EMPLOYEE NO.: | | |
|---------------------|---------------------|------------|------------|-------------|---------------|----------|-----------|
| JOB CLASSIFICATION: | | ITEM NO.: | WOR | K FACILITY: | | | |
| DEPARTMENT: | WORK | AREA/UNIT: | | | SHIFT | Γ: | PAY LOC.: |
| E-MAIL ADDRESS: | WORK | PHONE NO.: | CELI | /PAGER NO.: | SUPE | RVISOR N | AME: |

ANTI-NEOPLASTIC/HD ANNUAL QUESTIONNAIRE COMPLETED Reviewed Date: _____

| Initial Exam | Annual Exam | Exposure | Termination Exam |] Declination signed for | or Exam Surveillance |
|--------------|-------------|----------|------------------|--------------------------|----------------------|
| Height: | Weight: | BMI: | Temp: | P: | B/P: |
| ft in | lbs. | | | | |

| DATE | TEST | RESULT |
|------|------|--------|
| | | |
| | | |
| | | |
| | | |
| | | |

| PHYSICAL E | VALUATION | | | | |
|---|---|----------|----------------------------------|--|--|
| <u>Check each</u> item in the appropriate column. | NORMAL | ABNORMAL | DESCRIPTION OF ABNORMAL FINDINGS | | |
| General | | | | | |
| HEENT | | | | | |
| Lungs | | | | | |
| Heart | | | | | |
| Abdomen and Viscera | | | | | |
| Back/Spine | | | | | |
| Upper Extremities | | | | | |
| Lower Extremities | | | | | |
| Skin | | | | | |
| Neurologic | | | | | |
| Remarks: | | | | | |
| | Any identified medical conditions that need further evaluation or treatment? No Yes | | | | |
| Recommend 1 year interval for next exam Other | | | | | |

ANNUAL HAZARDOUS / ANTI-NEOPLASTIC DRUGS SPECIALTY MEDICAL EVALUATION

| Page 2 | of | 3 |
|--------|----|---|
|--------|----|---|

| | | | • |
|------------|---------------------|------------|---------------|
| LAST NAME: | FIRST, MIDDLE NAME: | BIRTHDATE: | EMPLOYEE NO.: |
| | | | |

PRINT AND PROVIDE A COPY OF THIS PAGE TO COUNTY WORKFORCE MEMBER

| HEALTHCARE PROFESSIONAL'S WRITTEN OPINION | | | | | |
|---|-------------------------------------|-------------------------|---------------|--|--|
| U Workforce member have been informed of the results | of evaluation. | | | | |
| Workforce member has been told about any medical treatment. | conditions resulting from exposure | which require further e | evaluation or | | |
| Print/provide copy of opinion to workforce member wi | thin 15 days of completion of the n | nedical evaluation. | | | |
| | COMMENTS: | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| | | | | | |
| Physician or Licensed Health Care Professional Signature | Print Name | License No. | Date | | |
| Address | | Phone No. | | | |

ANNUAL HAZARDOUS / ANTI-NEOPLASTIC DRUGS SPECIALTY MEDICAL EVALUATION

| Page | 3 | of | 3 |
|------|---|----|---|
|------|---|----|---|

| LAST NAME: | FIRST, MIDDLE NAME: | BIRTHDATE: | EMPLOYEE NO.: |
|------------|---------------------|------------|---------------|
| | | | |

GENERAL INSTRUCTIONS

In accordance with the Anti-Neoplastic and Hazardous Drug Medical Surveillance policy, workforce members who are routinely exposed to hazardous drugs will be enrolled and monitored as part of the medical surveillance program. This includes workforce members who directly handle drugs such as nursing staff, pharmacists, and pharmacy technicians. Occupational risk includes preparation, administration, and disposal of hazardous drugs.

Workforce member shall complete the Anti-Neoplastic/Hazardous Drug Evaluation/Questionnaire form, which contains the workforce member's medical and work history. The medical examination/questionnaire shall be conducted at pre-placement, annually, post-exposure, and exit /termination; and without cost to Department of Health Services workforce member. Identification of workforce members who need to be monitored will be made by Service Area Managers/Supervisors. Medical surveillance may be discontinued if the workforce member no longer works with anti-neoplastic/ hazardous agents.

Workforce member must sign the Declination of Medical Treatment if he/she declines the initial, annual, post-exposure or exit medical examination.

Non-County workforce members who have potential exposure to occupational hazards will be included in the surveillance program but will not have their assessments done through the County, unless specified in contract/agreement. Emergency services will be provided post-exposure within the allowable time frames, but will be billed to the contractor or agency, as appropriate.

Hazardous drug medical surveillance records shall be maintained for the duration of employment/assignment plus thirty (30) years, in accordance with 29 CFR 1910.1020 and 8 CCR §3204 of the General Industry Safety Orders.

DHS-EHS staff shall verify/review documentation(s) and record completion of this form for workforce member. This form and its attachment, if any, such as medical records shall be filed in workforce member's EHS medical file. All medical records of workforce member are confidential in accordance with federal, state and regulatory requirements.

DHS-EHS will obtain the workforce member's written consent before using or disclosing medical information, include to self, unless the disclosure is required by State or Federal law such as to a public health authority or governmental regulatory agency. An agency such as Cal-OSHA will need to provide a written order to access medical records with personally identifiable information. That written order will need to be posted at the facility upon such request. 8CCR §3204(e)(3)

Workforce members have the right to access their medical records and obtain a copy, thereof, within fifteen (15) days after the request.